Landscape Capital Management L.L.C. Makes New $573,000 Investment in Clover Health Investments, Corp. $CLOV

Key Points

• Landscape Capital Management L.L.C. has made a new investment in Clover Health Investments, purchasing 159,477 shares valued at approximately $573,000.
• CEO Conrad Wai sold 118,600 shares of Clover stock at an average price of $3.29, representing a 7.35% decrease in their position.
• Analyst ratings for Clover Health show an average rating of "Moderate Buy" with a consensus price target of $4.37.

Landscape Capital Management L.L.C. purchased a new position in shares of Clover Health Investments, Corp. (NASDAQ:CLOV - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 159,477 shares of the company's stock, valued at approximately $573,000.

A number of other large investors also recently bought and sold shares of CLOV. Millennium Management LLC raised its stake in Clover Health Investments by 5,071.2% during the fourth quarter. Millennium Management LLC now owns 1,245,701 shares of the company's stock worth $3,924,000 after purchasing an additional 1,221,612 shares during the period. Vanguard Group Inc. raised its stake in Clover Health Investments by 5.1% during the first quarter. Vanguard Group Inc. now owns 20,580,117 shares of the company's stock worth $73,883,000 after purchasing an additional 994,904 shares during the period. Schonfeld Strategic Advisors LLC purchased a new position in Clover Health Investments during the fourth quarter worth approximately $1,860,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Clover Health Investments by 90.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 830,457 shares of the company's stock worth $2,616,000 after purchasing an additional 394,881 shares during the period. Finally, Barclays PLC raised its stake in Clover Health Investments by 336.5% during the fourth quarter. Barclays PLC now owns 461,692 shares of the company's stock worth $1,454,000 after purchasing an additional 355,926 shares during the period. Hedge funds and other institutional investors own 19.77% of the company's stock.

Insiders Place Their Bets

In other news, CEO Conrad Wai sold 118,600 shares of the firm's stock in a transaction on Tuesday, July 22nd. The shares were sold at an average price of $3.29, for a total value of $390,194.00. Following the transaction, the chief executive officer owned 1,494,898 shares of the company's stock, valued at approximately $4,918,214.42. This trade represents a 7.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Anna U. Loengard purchased 26,500 shares of the company's stock in a transaction that occurred on Wednesday, August 13th. The shares were purchased at an average cost of $2.59 per share, for a total transaction of $68,635.00. Following the purchase, the director directly owned 29,610 shares in the company, valued at $76,689.90. This trade represents a 852.09% increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 24.07% of the company's stock.

Analyst Ratings Changes

CLOV has been the topic of a number of recent analyst reports. UBS Group cut their price target on shares of Clover Health Investments from $4.50 to $3.00 and set a "neutral" rating on the stock in a research note on Wednesday, August 6th. Canaccord Genuity Group cut their price target on shares of Clover Health Investments from $4.50 to $4.10 and set a "buy" rating on the stock in a research note on Thursday, August 7th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Clover Health Investments has an average rating of "Moderate Buy" and a consensus price target of $4.37.

Clover Health Investments Trading Down 0.4%

Shares of CLOV stock opened at $2.62 on Friday. The company's fifty day simple moving average is $2.78 and its 200-day simple moving average is $3.28. Clover Health Investments, Corp. has a 52 week low of $2.12 and a 52 week high of $4.87. The company has a market cap of $1.34 billion, a PE ratio of -32.75 and a beta of 1.91.

Clover Health Investments Company Profile

Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.